Skip to content

AETERNUM HEALTH, INC.: 10-Q filed 2025-11-13

What AETERNUM HEALTH, INC. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 30 published measures, 90 facts as tagged in accession 0001493152-25-022091.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-13
Fiscal period
fiscal Q3 2025
Accession
0001493152-25-022091 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AETERNUM HEALTH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3074,054USD
At 2024-12-3165,417USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-301,973,670USD
At 2024-12-311,741,439USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-30-1,899,616USD
At 2025-06-30-1,761,756USD
At 2025-03-31-1,655,901USD
At 2024-12-31-1,676,022USD
At 2024-09-30-1,536,709USD
At 2024-06-30-1,459,514USD
At 2024-03-31-1,343,231USD
At 2023-12-31-1,225,704USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-300USD
At 2024-12-310USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-137,860USD92
2025-01-01 to 2025-09-30-237,824USD273
2025-04-01 to 2025-06-30-105,855USD91
2025-01-01 to 2025-03-315,891USD90
2024-07-01 to 2024-09-30-77,195USD92
2024-01-01 to 2024-09-30-311,005USD274
2024-04-01 to 2024-06-30-116,283USD91
2024-01-01 to 2024-03-31-117,527USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-3035,549USD273
2024-01-01 to 2024-09-30-152,998USD274

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-07-01 to 2025-09-308,345USD92
2025-01-01 to 2025-09-30180,124USD273
2024-07-01 to 2024-09-3015,442USD92
2024-01-01 to 2024-09-3052,779USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-113,244USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-3,178,871USD
At 2024-12-31-2,941,047USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-3049,190,204shares92
2025-01-01 to 2025-09-3048,999,942shares273
2024-07-01 to 2024-09-3048,478,678shares92
2024-01-01 to 2024-09-3048,478,678shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-3049,190,204shares92
2025-01-01 to 2025-09-3048,999,942shares273
2024-07-01 to 2024-09-3048,478,678shares92
2024-01-01 to 2024-09-3048,478,678shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-300USD/shares92
2025-01-01 to 2025-09-300USD/shares273
2024-07-01 to 2024-09-300USD/shares92
2024-01-01 to 2024-09-300USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-300USD/shares92
2025-01-01 to 2025-09-300USD/shares273
2024-07-01 to 2024-09-300USD/shares92
2024-01-01 to 2024-09-300USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-3014,230USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-120,943USD92
2025-01-01 to 2025-09-30-186,921USD273
2024-07-01 to 2024-09-30-110,084USD92
2024-01-01 to 2024-09-30-308,094USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-3073,054USD
At 2024-12-3164,417USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-301,053,991USD
At 2024-12-31821,761USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-30843USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-30112,326USD92
2025-01-01 to 2025-09-30298,014USD273
2024-07-01 to 2024-09-3095,200USD92
2024-01-01 to 2024-09-30297,604USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-3018,330USD
At 2024-12-3144,763USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-8,617USD92
2025-01-01 to 2025-09-30111,093USD273
2024-07-01 to 2024-09-30-14,884USD92
2024-01-01 to 2024-09-30-10,490USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-3049,190,204shares
At 2024-12-3148,478,678shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-30809,807USD
At 2024-12-31802,692USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-301,000USD
At 2024-12-311,000USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-3037,686USD92
2025-01-01 to 2025-09-3078,214USD273
2024-07-01 to 2024-09-3012,045USD92
2024-01-01 to 2024-09-3048,577USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-07-01 to 2025-09-3016,917USD92
2025-01-01 to 2025-09-3050,903USD273
2024-07-01 to 2024-09-3017,111USD92
2024-01-01 to 2024-09-3052,911USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-16,917USD92
2025-01-01 to 2025-09-30-50,903USD273
2024-07-01 to 2024-09-3032,889USD92
2024-01-01 to 2024-09-30-2,911USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-09-301,956USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30842USD273
2024-01-01 to 2024-09-3014,799USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-26,433USD273
2024-01-01 to 2024-09-3027,680USD274

Inspect the source

Entity
AETERNUM HEALTH, INC. / CIK 0000764630
Captured
2026-09-19T15:02:38.824Z
SEC response SHA-256
6c9d70d4b82a4edc5f4de8082c897762179c66ba1d127e497154b6262edf21b8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000764630.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))